Burkman R T, Bell W R, Zacur H A, Kimball A W
Department of Gynecology-Obstetrics, Henry Ford Hospital, Detroit, MI 48202.
Am J Obstet Gynecol. 1991 Jun;164(6 Pt 1):1453-8; discussion 1458-60. doi: 10.1016/0002-9378(91)91424-u.
A randomized clinical trial of oral contraceptives evaluated 67 women on a regimen of 50 micrograms ethinyl estradiol and 1.0 mg norethindrone, 61 women on a regimen of 35 micrograms ethinyl estradiol and 1.0 mg norethindrone, and 64 women on a regimen of 35 micrograms ethinyl estradiol and 0.5 mg norethindrone. ABO blood group type was determined in all women. At baseline and at 3, 6, and 9 months, plasma antithrombin III levels, by both an immunologic and an activity method, and selected plasma levels of the contraceptive steroids were measured. Antithrombin III levels for all oral contraceptive groups combined decreased from baseline by 19.7% and 28.8% for the immunologic and activity methods, respectively. Analysis of interrelationships among antithrombin III by activity method, oral contraceptive type, and ABO blood group showed larger declines in antithrombin III for type O women using the highest estrogen dose preparation (31.6%) and for non-type O women using the lowest progestin dose preparation (38.9%). Plasma levels of contraceptive steroids also were related to changes in the most extreme levels of antithrombin III.
一项口服避孕药的随机临床试验评估了67名服用含50微克炔雌醇和1.0毫克炔诺酮方案的女性、61名服用含35微克炔雌醇和1.0毫克炔诺酮方案的女性以及64名服用含35微克炔雌醇和0.5毫克炔诺酮方案的女性。测定了所有女性的ABO血型。在基线以及第3、6和9个月时，通过免疫学法和活性法测定血浆抗凝血酶III水平，并测定避孕药类固醇的选定血浆水平。所有口服避孕药组的抗凝血酶III水平合并后，免疫学法和活性法分别较基线下降了19.7%和28.8%。活性法抗凝血酶III、口服避孕药类型和ABO血型之间的相互关系分析显示，使用最高雌激素剂量制剂的O型女性（31.6%）和使用最低孕激素剂量制剂的非O型女性（38.9%）的抗凝血酶III下降幅度更大。避孕药类固醇的血浆水平也与抗凝血酶III的最极端水平变化有关。
